metricas
covid
Buscar en
Clinics
Toda la web
Inicio Clinics Perioperative management of drugs commonly used in patients with rheumatic disea...
Información de la revista
Vol. 72. Núm. 6.
Páginas 386-390 (enero 2016)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
2953
Vol. 72. Núm. 6.
Páginas 386-390 (enero 2016)
REVIEW
Open Access
Perioperative management of drugs commonly used in patients with rheumatic diseases: a review
Visitas
2953
André Silva Franco, Leandro Ryuchi Iuamoto, Rosa Maria Rodrigues Pereira
Autor para correspondencia
rosamariarp@yahoo.com

Corresponding author
Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, BR
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas

Rheumatic diseases are very prevalent, affecting about 7 million people in North America; they affect the musculoskeletal system, often with systemic involvement and potential for serious consequences and limitation on quality of life. Clinical treatment is usually long-term and includes drugs that are considered either simple or complex and are occasionally unknown to many health professionals who do not know how to manage these patients in emergency units and surgical wards. Thus, it is important for clinicians, surgeons and anesthesiologists who are involved with rheumatic patients undergoing surgery to know the basic principles of therapy and perioperative management. This study aims to do a review of the perioperative management of the most commonly used drugs in rheumatologic patients. Manuscripts used in this review were identified by surveying MEDLINE, LILACS, EMBASE, and COCHRANE databases and included studies containing i) the perioperative management of commonly used drugs in patients with rheumatic diseases: and ii) rheumatic diseases. They are didactically discussed according to the mechanism of action and pharmacokinetics; and perioperative management. In total, 259 articles related to the topic were identified. Every medical professional should be aware of the types of drugs that are appropriate for continuous use and should know the various effects of these drugs before indicating surgery or assisting a rheumatic patient postoperatively. This information could prevent possible complications that could affect a wide range of patients.

KEYWORDS:
Rheumatic Diseases
Drugs
Perioperative Period
Inflammation Mediators
Texto completo
INTRODUCTION

Rheumatic diseases are very prevalent, affecting about 7 million people in North America 1; they affect the musculoskeletal system, often with systemic involvement and potential for serious consequences and limitation on quality of life 2,3. The diagnoses of such diseases are not simple and may require additional tests and multidisciplinary approaches 4. Clinical treatment is usually long-term, using drugs that are considered either simple or complex and are occasionally unknown to many health professionals. Such a lack of understanding could lead to difficulty in managing these patients in primary care services, emergency units and surgical wards 4.

An estimated 33 million patients undergo surgical procedures each year in the United States. Serious adverse events occur in more than 1 million of these patients at an annual estimated cost of US$ 25 billion. With an aging population, it is expected that surgical indications and surgical costs will increase by 25% and 50%, respectively, and that the cost of perioperative complications will double 5.

The incidence of postoperative infections ranges from 0.5 to 6.0%, depending on the medical center, the type of surgery, and the surgical site 6. Rheumatic patients, however, are at increased risk of developing postoperative infections. Approximately 25% of all patients with rheumatoid arthritis will require surgery within the first 20 years of disease, excluding emergency procedures not related to preexisting maladies. The major complication of elective orthopedic procedures is surgical site infection, with an incidence between 2-15% and the drugs used by these patients cannot be ruled out as a contributing factors to such high rates 7–11.

Considering the epidemiology of such diseases and professional accountability for the use of prescribed drugs, it is imperative that clinicians, surgeons and anesthesiologists who are involved with rheumatic patients undergoing surgery know the basic principles of drug therapy and perioperative management 12–14.

The purpose of the present study is to evaluate the drugs that are most commonly used in patients with rheumatic diseases and to guide the perioperative management of these drugs.

METHODS

Manuscripts used in this review were identified by surveying MEDLINE, LILACS, EMBASE, and COCHRANE databases and included studies containing i) the perioperative management of commonly used drugs in patients with rheumatic diseases: nonsteroidal anti-inflammatory drugs, glucocorticoids, disease-modifying antirheumatic drugs and biological drugs; and ii) rheumatic diseases: Behçet Syndrome, Dermatomyositis, Gout, Juvenile Arthritis, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatic Fever, Rheumatoid Arthritis, Sjogren's Syndrome, Spondyloarthropathies, Still's Disease, Systemic Lupus Erythematosus, Systemic Scleroderma, and Vasculitis.

There were no time or language restrictions and the last search dates back from 30 April 2016 for all databases. Articles discussing bone metabolism and cardiovascular events were excluded.

Initially, throughout all the data from the selected articles, we sought for 1 the rheumatic disease(s) each of them studied; 2 the drugs used by the patients; 3 the type of surgery; and 4 the perioperative management. Finally, we extracted the results of each article and organized them according to these aforementioned four items.

The selected items and results are discussed in this review according to the following breakdown:

  • mechanism of action and pharmacokinetics of the main drugs used to control rheumatic diseases;

  • perioperative management of the commonly used drugs in patients with rheumatic diseases.

RESULTS

The search of MEDLINE, EMBASE, LILACS and COCHRANE databases provided 237 studies. After removing the duplicates, 223 remained. Of these, 18 studies were not full text; and 172 were discarded because after reviewing the abstracts these papers clearly did not meet the eligibility criteria. Twelve additional studies that met the criteria for inclusion were identified by checking the references of other relevant papers that did not meet our criteria. The full texts of the remaining 45 citations were examined in more detail. No unpublished relevant studies were obtained. 6 articles were not used in this review based on our exclusion criteria.

It is also important to note the lack of randomized, double-blind researches/trials comparing the safety of drugs in rheumatic diseases in emergency procedures and not only in elective surgeries.

In our review, we only found articles about rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis, excluding any other rheumatic diseases. Regarding the treatment and perioperative management of such conditions, we found information on Nonsteroidal antiinflammatory drugs and aspirin (NSAIDs), glucocorticoids, Disease-modifying antirheumatic drugs (DMARDs) and biological drugs, presented as follows.

Aspirin and Nonsteroidal anti-inflammatory drugs (NSAIDs)

The inhibition of COX-1 by aspirin and other NSAIDs results in increased bleeding time. This effect is lasting due to the inhibition of platelet COX and it is reversed only after drug withdrawal, which is considered to be effective after 4 to 5 half-lives. Thus, it is important to remember that depending on the average half-life of a particular NSAID, it should be suspended for hours or even days before surgical procedure.

Regarding COX-2 inhibitors, drugs that have minimal effects on platelet function 15, withdrawal during the perioperative period is not required (Table 1).

Table 1.

Nonsteroidal anti-inflammatory drugs.

NSAID  Half-life (hours)  Withdrawal before surgery 
Naproxen  12-15  3 days 
Ibuprofen  1.6-1.9  10 hours 
Diclofenac  10 hours 
Indomethacin  4.5  1 day 
COX-2 inhibitor (Celecoxib)  11  maintain usual dosage 

Adapted from reference 21.

For patients who are in need of continuing aspirin treatment to manage the risk of thromboembolism / ischemia, no changes in dosage are indicated because the cardiovascular risk outweighs the intraoperative benefits of altering the drug intake 16–18. In such cases, the surgeon must be aware of this condition and be prepared for bleeding complications during the intraoperative period 19–22. Although Tytgat et al. 23 did not show differences in surgeons' assessment of intraoperative bleeding in carotid endarterectomy among patients who stopped aspirin before surgery and those who continued aspirin intake. In fact, postoperative complications like hematomas were not significantly increased, even in surgeries including cholecystectomy, appendectomy, open or laparoscopic inguinal hernia repair, liver surgery and hip and knee arthroscopy 16,24,25. Current guideline suggests to not withdraw aspirin for secondary cardiovascular prevention before surgeries 19.

Considering rheumatic patients, the use of NSAIDs is indicated to prevent heterotopic ossification after arthroplasty, especially in patients with ankylosing spondylitis and psoriatic arthritis, for whom Indomethacin (75-100 mg/day) or Celecoxib (400 mg/day) are recommended before the fifth postoperative day, optimally within 24 to 48 hours, for 20 days after surgery 22,26,27.

Glucocorticoid prescription due to Hypothalamic-Pituitary-Adrenal axis suppression

Hypothalamic-pituitary-adrenal axis suppression occurs in patients who are on chronic use of glucocorticoids. If the doses are above the physiologic range (10-12 mg of cortisol/day), 30 days is probably the minimal for inhibition of endogenous glucocorticoid synthesis. There is evidence that the use of 20 mg of prednisone for 5 days is already sufficient to inhibit cortisol synthesis 28. In such cases, it is necessary to supplement the glucocorticoid dose in the perioperative period due to surgical stress, even with the increased risk of infection and hindering of wound healing induced by these drugs 29,30 (Table 2).

Table 2.

Glucocorticoid prescription according to surgical aggression.

Type of surgery / surgical stress  Surgical Procedures  Glucocorticoid prescription 
Superficial procedure (anesthesia <1 hour)  Ophthalmologic surgeries, herniorrhaphy  Not necessary.Maintain daily dosage. 
Small surgical stress  Carpal tunnel release, colonoscopy, knee arthroscopy  25 mg hydrocortisone IV or 5 mg methylprednisolone IV on the procedure day 
Mild surgical stress  hip arthroplasty, knee arthroplasty, laparoscopic abdominal surgery, pulmonary biopsy  50-75 mg hydrocortisone IV or 10-15 mg methylprednisolone IV on the procedure day 
Important surgical stress  bilateral hip arthroplasty, total ankle arthroplasty, spine surgery, open abdominal surgery, hysterectomy  100-150 mg hydrocortisone IV or 30 mg methylprednisolone IV on the procedure day; return to previous dosage by lowering it on the next 1 to 2 days 

Adapted from references 14 and 34.

A decade ago, high doses of corticosteroids were given to patients with adrenal insufficiency before surgery. More recent studies prefer to assess therapy length, corticosteroid dose and degree of surgical stress to prescribe the minimum amount of drug 31 (Table 2). An ACTH stimulation test could be performed during preoperative evaluation to verify the need for corticosteroid supplementation 32, although the low sensitivity observed in patients with secondary adrenal insufficiency frequently requires additional testing 33.

Disease-modifying antirheumatic drugs

Disease-modifying antirheumatic drugs (DMARDs) are a heterogeneous group of drugs and their main benefit is to delay the progression of some rheumatologic diseases by changing its natural history. Most prospective and retrospective studies have suggested that methotrexate and other DMARDs may be continued during the perioperative period without compromising healing or increasing the risk of infection 12,34.

Hydroxychloroquine in lupus patients, reduces disease activity, cardiovascular risk, insulin resistance, thromboembolic events, infection risk and mortality 35–38, and this drug should not be discontinued during the perioperative period.

Table 3 summarizes the half-life, mechanism of action, side effects and management regarding the perioperative period.

Table 3.

DMARDs - mechanism of action, half-life and management in the perioperative period.

Drug  Half-life  Mechanism of action  Management 
Methotrexate  3-10 hours  Dihydrofolate reductase inhibition  Maintain usual dosage* 
Hydroxychloroquine  32-50 hours  Lysosomal membrane stabilization and reduces IL-1 and TNF synthesis  Maintain usual dosage 
Leflunomide  2 weeks  Pyrimidine synthesis inhibitor - lowers B and T cell population  Withdraw 2 weeks before surgery; resume after 3 days (controversial) 
Ciclosporin  5-18 hours  Inhibits T cell activation by inhibiting calcineurin – cyclophilin ligand  Withdraw 1 week before and 1 week after surgery 
Azathioprine  1-3 hours  Purine synthesis inhibition – inhibits cell proliferation  Maintain usual dosage 
Mycophenolate mofetil  16-18 hours  Restricts T and B cell proliferation – action upon purine-synthesising enzyme  Withdraw 1 week before surgery; resume 1 to 2 weeks after surgery 

Adapted from references 12, 34, 39, 40 and 41.

*

in special situations (Chronic kidney disease, poorly controlled diabetes mellitus, etc.): methotrexate should be suspended one week before.

Biological drugs

Biological agents are newer, high cost drugs with specific mechanisms of action for each molecule - they are antibodies against a target molecule. Within rheumatology, the main agents used are those that antagonize TNF, IL-1, IL-6, CD20 and costimulatory molecules. The mechanism of action, half-life, management during the perioperative period and main side effects of each of the various biologic agents are summarized in Table 4.

Table 4.

Biological agents - Half-life, mechanism of action, management during perioperative period and major side effects.

Drug  Half-life  Mechanism of action  Management  Side effects 
Etanercept  3.5 – 5.5 days  Anti-TNFWithdraw 10 days before surgery  Increased risk of infection
Adalimumab  10 – 20 days  Withdraw 30 days before surgery 
Infliximab  9.5 days  Withdraw 19 days before surgery 
Certolizumab  14 days  Withdraw 28 days before surgery 
Golimumab  14 days  Withdraw 28 days before surgery 
Abatacept  12.6 days  T cell inhibitor  Withdraw 25 days before surgery  Increased risk of infection, headache, gastrointestinal disorders 
Rituximab  18 – 22 days (effects can last for months)  B cell inhibitor  Withdraw 100 days before surgery  Increased risk of infection, Stevens-Johnson syndrome, hypotension, arrhythmias 
Tocilizumab  11 – 13 days  IL-6 receptor antagonist  Withdraw 26 days before surgery  Increased risk of infection, hepatotoxicity 
Anakinra  4 – 6 hours  IL-1 receptor antagonist  Withdraw 1 to 2 days before surgery  Increased risk of infection, hepatotoxicity 

Adapted from reference 34.

For minor procedures, there is no need to interrupt most of these agents, since there is no evidence of increased risk of infection or impaired healing of the surgical site 12. However, for major surgeries, their interruption is recommended for at least twice their half-lives before surgery and may be resumed from 10 to 14 days after surgery 9,39–43, since all of these agents increase the risk of infections. Some drugs, as rituximab, an anti-CD20 monoclonal antibody that depletes populations of B lymphocytes, have a longstanding effect, beginning 2 to 3 weeks after drug introduction and lasting up to 12 months after withdrawal. Severe hypogammaglobinemia is a rare adverse effect of rituximab that could lead to infections. Serum IgG levels may be assessed prior to surgery and patients with low values (IgG < 500 mg/L) may receive intravenous immunoglobulin replacement therapy 44,45.

More studies are necessary to develop guidelines with strong evidence about the safety and management of drugs in the perioperative period in patients with rheumatic diseases. The differentiation of elective procedures and emergency surgeries would also be an important matter for the medical community to reduce infections and complications after surgery.

CONCLUSION

Knowing the various drugs used in patients with rheumatic diseases is necessary because their side effects can modify the progression of the postoperative period. Hence, every physician, before suggesting surgical procedures or following the postoperative evolution of a rheumatic patient, should be capable of managing continuous-use drugs. The most important measures to remember are: a) Aspirin intake for secondary cardiovascular prevention should be maintained during perioperative period for most surgeries; b) NSAIDs should be suspended for hours or even days according to half-life time before surgical procedure; c) Glucocorticoid prescription must be made according to surgical stress; d) Methotrexate, hydroxychloroquine and azathioprine should be maintained during perioperative period; e) biological agents are recommended to be suspended 2 half-lives prior to surgery; f) the administration of such drugs should be restarted based on clinical status and absence of complications (infections and bleeding).

AUTHOR CONTRIBUTIONS

Franco AS, Iuamoto LR and Pereira RM were responsible for the study design, critical analysis, manuscript drafting and approval of the final version of the manuscript. Franco AS and Iuamoto LR were responsible for the literature review. Franco AS and Pereira RM were responsible for revising the manuscript content. All the authors take responsibility for the integrity of the data analysis.

ACKNOWLEDGMENTS

This study was supported by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq #301805/2013-0 to RMRP) and Federico Foundation (to RMRP).

REFERENCES
[1]
CG Helmick , DT Felson , RC Lawrence , S Gabriel , R Hirsch , CK Kwoh , et al.
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States Part I.
[2]
H Radner , K Yoshida , JS Smolen , DH Solomon .
Multimorbidity and rheumatic conditions-enhancing the concept of comorbidity.
[3]
A Marsico , F Atzeni , A Piroddi , M Cazzola , S Stisi , P Sarzi-Puttini .
Costs of pain in rheumatology.
[4]
WP Arend , G V Lawry .
APPROACH TO THE PATIENT WITH RHEUMATIC DISEASE.
Goldman’s Cecil Medicine, 24th ed,
[6]
T Bongartz .
Elective orthopedic surgery and perioperative DMARD management: many questions, fewer answers, and some opinions….
J Rheumatol, 34 (2007), pp. 653-655
[7]
R Poss , TS Thornhill , FC Ewald , WH Thomas , NJ Batte , CB Sledge .
Factors influencing the incidence and outcome of infection following total joint arthroplasty.
Clin Orthop Relat Res, (1984), pp. 117-126
[8]
JC Schrama , B Espehaug , G Hallan , LB Engesaeter , O Furnes , LI Havelin , et al.
Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective, population-based study on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplast Register.
Arthritis Care Res, 62 (2010), pp. 473-479
[9]
L Goh , T Jewell , C Laversuch , A Samanta .
Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence.
[10]
AL Smitten , HK Choi , MC Hochberg , S Suissa , TA Simon , MA Testa , et al.
The risk of hospitalized infection in patients with rheumatoid arthritis.
J Rheumatol, 35 (2008), pp. 387-393
[11]
MF Doran , CS Crowson , GR Pond , WM O’Fallon , SE Gabriel .
Predictors of infection in rheumatoid arthritis.
[12]
BM Akkara Veetil , T Bongartz .
Perioperative care for patients with rheumatic diseases.
[13]
P Härle , RH Straub , M Fleck .
Elective surgery in rheumatic disease and immunosuppression: to pause or not.
[14]
CR Howe , GC Gardner , NJ Kadel .
Perioperative medication management for the patient with rheumatoid arthritis.
[15]
PT Leese , RC Hubbard , A Karim , PC Isakson , SS Yu , GS Geis .
Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial.
[16]
A Oscarsson , A Gupta , M Fredrikson , J Järhult , M Nyström , E Pettersson , et al.
To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial.
[17]
H Möllmann , HM Nef , CW Hamm .
Clinical pharmacology: antiplatelet therapy during surgery.
[18]
NS Gerstein , MC Carey , JE Cigarroa , PM Schulman .
Perioperative aspirin management after POISE-2: some answers, but questions remain.
Anesth Analg, 120 (2015), pp. 570-575
[19]
JD Douketis , AC Spyropoulos , FA Spencer , M Mayr , AK Jaffer , MH Eckman , et al.
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
[20]
O Mathiesen , J Wetterslev , VK Kontinen , HC Pommergaard , L Nikolajsen , J Rosenberg , et al.
Adverse effects of perioperative paracetamol, NSAIDs, glucocorticoids, gabapentinoids and their combinations: a topical review.
Acta Anaesthesiol Scand, 58 (2014), pp. 1182-1198
[21]
CS Connelly , RS Panush .
Should nonsteroidal anti-inflammatory drugs be stopped before elective surgery.
Arch Intern Med, 151 (1991), pp. 1963-1966
[22]
R Slappendel , EW Weber , B Benraad , R Dirksen , ML Bugter .
Does ibuprofen increase perioperative blood loss during hip arthroplasty.
[23]
SHAJ Tytgat , DM Laman , AM Rijken , R Klicks , A Voorwinde , JM Ultee , et al.
Emboli rate during and early after carotid endarterectomy after a single preoperative dose of 120 mg acetylsalicylic acid–a prospective double-blind placebo controlled randomised trial.
[24]
W Ong , T Shen , WB Tan , D Lomanto .
Is preoperative withdrawal of aspirin necessary in patients undergoing elective inguinal hernia repair.
[25]
VA Ferraris , E Swanson .
Aspirin usage and perioperative blood loss in patients undergoing unexpected operations.
Surg Gynecol Obstet, 156 (1983), pp. 439-442
[26]
H Kienapfel , M Koller , A Wüst , C Sprey , H Merte , R Engenhart-Cabillic , et al.
Prevention of heterotopic bone formation after total hip arthroplasty: a prospective randomised study comparing postoperative radiation therapy with indomethacin medication.
[27]
R Iorio , WL Healy .
Heterotopic ossification after hip and knee arthroplasty: risk factors, prevention, and treatment.
[28]
L Axelrod .
Perioperative management of patients treated with glucocorticoids.
[29]
AE Stuck , CE Minder , FJ Frey .
Risk of infectious complications in patients taking glucocorticosteroids.
[30]
AS Wang , EJ Armstrong , AW Armstrong .
Corticosteroids and wound healing: clinical considerations in the perioperative period.
[31]
M Salem , RE Tainsh , J Bromberg , DL Loriaux , B Chernow .
Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem.
[32]
H Kehlet , C Binder .
Value of an ACTH test in assessing hypothalamic-pituitary-adrenocortical function in glucocorticoid-treated patients.
[33]
RI Dorin , CR Qualls , LM Crapo .
Diagnosis of adrenal insufficiency.
[34]
G Gardner .
Management of medications in patients with rheumatic diseases during the perioperative period.
Perioperative Management of Patients with Rheumatic Disease,
[35]
LF Muniz , RM Pereira , TF Silva , E Bonfa , EF Borba .
Impact of therapy on metabolic syndrome in young adult premenopausal female lupus patients: Beneficial effect of antimalarials.
Arthritis Care Res, 67 (2015), pp. 1255-1262
[36]
SK Shinjo , E Bonfá , D Wojdyla , EF Borba , LA Ramirez , HR Scherbarth , et al.
Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort.
[37]
G Ruiz-Irastorza , N Olivares , I Ruiz-Arruza , A Martinez-Berriotxoa , MV Egurbide , C Aguirre .
Predictors of major infections in systemic lupus erythematosus.
[38]
A Danza , G Ruiz-Irastorza .
Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies.
[39]
P Härle , RH Straub , M Fleck .
Perioperative management of immunosuppression in rheumatic diseases–what to do.
[40]
E Berthold , P Geborek , A Gülfe .
Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures.
[41]
SM Goodman , S Paget .
Perioperative drug safety in patients with rheumatoid arthritis.
[42]
Y Hirano , T Kojima , Y Kanayama , T Shioura , M Hayashi , D Kida , et al.
Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis.
[43]
AA den Broeder , MC Creemers , J Fransen , E de Jong , DJ de Rooij , A Wymenga , et al.
Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study.
J Rheumatol, 34 (2007), pp. 689-695
[44]
MH Buch , JS Smolen , N Betteridge , FC Breedveld , G Burmester , T Dörner , et al.
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.
[45]
H Marco , RM Smith , RB Jones , MJ Guerry , F Catapano , S Burns , et al.
The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.

No potential conflict of interest was reported.

Copyright © 2017. CLINICS
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos